Large Cell Neuroendocrine Carcinoma of Prostate
- 1 June 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 30 (6), 684-693
- https://doi.org/10.1097/00000478-200606000-00003
Abstract
Neuroendocrine (NE) differentiation in prostate cancer is typically detected by immunohistochemistry as single cells in conventional adenocarcinoma. Prostatic NE tumors, such as carcinoid or small cell carcinoma, are rare and large cell NE carcinoma (LCNEC) is described only in case reports. We identified 7 cases of LCNEC and compiled their clinicopathologic characteristics. In 6 cases, there was a history of adenocarcinoma treated with hormone therapy for a mean of 2.4 years (range: 2 to 3 y). The remaining case was de novo LCNEC. LCNEC was incidentally diagnosed in palliative transurethral resection specimens in 5 cases. The mean patient age at diagnosis with LCNEC was 67 years (range: 43 to 81 y). LCNEC comprised solid sheets and ribbons of cells with abundant pale to amphophilic cytoplasm, large nuclei with coarse chromatin and prominent nucleoli along with brisk mitotic activity and foci of necrosis. In 6 cases, there were foci of admixed adenocarcinoma, 4 of which showed hormone therapy effects. LCNEC was strongly positive for CD56, CD57, chromogranin A, synaptophysin, and P504S/alpha methylacyl CoA racemase. There was strong bcl-2 overexpression, expression of MIB1, and p53 in >50% of nuclei, focally positive staining for prostate specific antigen and prostatic acid phosphatase and negative androgen receptor staining. Follow-up was available for 6 patients, all of who died with metastatic disease at mean of 7 months (range: 3 to 12 mo) after platinum-based chemotherapy. LCNEC of prostate is a distinct clinicopathologic entity that typically manifests after long-term hormonal therapy for prostatic adenocarcinoma and likely arises through clonal progression under the selection pressure of therapy.Keywords
This publication has 36 references indexed in Scilit:
- GENETICALLY MODIFIED MICE AND THEIR USE IN DEVELOPING THERAPEUTIC STRATEGIES FOR PROSTATE CANCERJournal of Urology, 2004
- Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft modelThe Prostate, 2004
- Metastatic Carcinoid Tumor of the ProstateJournal of Urology, 2002
- Prostate carcinoma with neuroendocrine differentiation: case report and literature reviewRevista Do Hospital Das Clinicas, 2001
- TRANSDIFFERENTIATION OF PROSTATE CANCER CELLS TO A NEUROENDOCRINE CELL PHENOTYPE IN VITRO AND IN VIVOJournal of Urology, 1999
- Kinetics of Neuroendocrine Differentiation in an Androgen-Dependent Human Prostate Xenograft ModelThe American Journal of Pathology, 1999
- The Prognostic Value of Neuroendocrine Differentiation in Adenocarcinoma of the Prostate in Relation to Progression of Disease After Endocrine TherapyJournal of Urology, 1997
- Neuroendocrine Tumors of the Lung With Proposed Criteria for Large-Cell Neuroendocrine CarcinomaThe American Journal of Surgical Pathology, 1991
- Small cell carcinoma of the prostate part I a clinicopathologic study of 20 casesCancer, 1987
- Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment?Journal of Clinical Pathology, 1986